{
    "end": 4, 
    "mention": "ten-electrode", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 3.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 6, 
    "mention": "lasso-shaped", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 5.0, 
    "type": "Hazardous_or_Poisonous_Substance"
}
{
    "end": 7, 
    "mention": "cathe-ter", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 6.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 9, 
    "mention": "allows", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 8.0, 
    "type": "Social_Behavior"
}
{
    "end": 10, 
    "mention": "irrigated", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 9.0, 
    "type": "Functional_Concept"
}
{
    "end": 11, 
    "mention": "unipolar", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 10.0, 
    "type": "Spatial_Concept"
}
{
    "end": 13, 
    "mention": "bi-polar", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 12.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 20, 
    "mention": "cool", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 19.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 21, 
    "mention": "flow", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 20.0, 
    "type": "Natural_Phenomenon_or_Process"
}
{
    "end": 23, 
    "mention": "60", 
    "pid": 0, 
    "senid": 5, 
    "sent": "This is a ten-electrode steerable lasso-shaped cathe-ter that allows irrigated unipolar and bi-polar radiofrequency -LRB- RF -RRB- ablation -LRB- cool flow of 60 ml/min -RRB- .", 
    "start": 22.0, 
    "type": "Finding"
}
{
    "end": 2, 
    "mention": "septal", 
    "pid": 0, 
    "senid": 17, 
    "sent": "The septal and lateral PVs were isolated .", 
    "start": 1.0, 
    "type": "Spatial_Concept"
}
{
    "end": 4, 
    "mention": "lateral", 
    "pid": 0, 
    "senid": 17, 
    "sent": "The septal and lateral PVs were isolated .", 
    "start": 3.0, 
    "type": "Spatial_Concept"
}
{
    "end": 5, 
    "mention": "PVs", 
    "pid": 0, 
    "senid": 17, 
    "sent": "The septal and lateral PVs were isolated .", 
    "start": 4.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 8, 
    "mention": "isolated .", 
    "pid": 0, 
    "senid": 17, 
    "sent": "The septal and lateral PVs were isolated .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 2, 
    "mention": "58-year-old", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 1.0, 
    "type": "Temporal_Concept"
}
{
    "end": 3, 
    "mention": "patient", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 2.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 11, 
    "mention": "history of paroxysmal atrial fibrillation", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 6.0, 
    "type": "Finding"
}
{
    "end": 9, 
    "mention": "paroxysmal", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 8.0, 
    "type": "Temporal_Concept"
}
{
    "end": 13, 
    "mention": "circumferential", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 12.0, 
    "type": "Spatial_Concept"
}
{
    "end": 15, 
    "mention": "pulmonary vein", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 13.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 16, 
    "mention": "isolation", 
    "pid": 0, 
    "senid": 1, 
    "sent": "A 58-year-old patient with a 3-year history of paroxysmal atrial fibrillation underwent circumferential pulmonary vein isolation -LRB- PVI -RRB- in 2012 .", 
    "start": 15.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 3, 
    "mention": "transthoracic echocardiogram", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 1.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 4, 
    "mention": "revealed", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 3.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "pericardial effusion", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 4.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 8, 
    "mention": "collapsed", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 7.0, 
    "type": "Functional_Concept"
}
{
    "end": 9, 
    "mention": "right", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 8.0, 
    "type": "Spatial_Concept"
}
{
    "end": 9, 
    "mention": "chambers ", 
    "pid": 11, 
    "senid": 1, 
    "sent": "5", 
    "start": NaN, 
    "type": "Manufactured_Object"
}
{
    "end": 12, 
    "mention": "suggesting", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 11.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 15, 
    "mention": "cardiac tamponade .", 
    "pid": 1, 
    "senid": 5, 
    "sent": "The transthoracic echocardiogram revealed pericardial effusion with collapsed right chambers , suggesting cardiac tamponade .", 
    "start": 12.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 3, 
    "mention": "hospital course", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 1.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 5, 
    "mention": "further", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 4.0, 
    "type": "Spatial_Concept"
}
{
    "end": 6, 
    "mention": "complicated", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 9, 
    "mention": "severe ARDS", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 7.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 9, 
    "mention": "ARDS", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 8.0, 
    "type": "Mental_Process"
}
{
    "end": 8, 
    "mention": "severe", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 7.0, 
    "type": "Intellectual_Product"
}
{
    "end": 11, 
    "mention": "secondary to", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 9.0, 
    "type": "Temporal_Concept"
}
{
    "end": 13, 
    "mention": "Enterococcus faecalis", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 11.0, 
    "type": "Bacterium"
}
{
    "end": 14, 
    "mention": "bacteremia", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 13.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 16, 
    "mention": "redo", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 15.0, 
    "type": "Temporal_Concept"
}
{
    "end": 17, 
    "mention": "veno-venous", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 16.0, 
    "type": "Spatial_Concept"
}
{
    "end": 19, 
    "mention": "ECMO .", 
    "pid": 1, 
    "senid": 9, 
    "sent": "Her hospital course was further complicated by severe ARDS secondary to Enterococcus faecalis bacteremia with redo veno-venous ECMO .", 
    "start": 17.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 1, 
    "mention": "Conduction", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 0.0, 
    "type": "Organ_or_Tissue_Function"
}
{
    "end": 6, 
    "mention": "left pulmonary veins", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 3.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 9, 
    "mention": "present", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 8.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 13, 
    "mention": "gap", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 12.0, 
    "type": "Spatial_Concept"
}
{
    "end": 16, 
    "mention": "bottom", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 15.0, 
    "type": "Spatial_Concept"
}
{
    "end": 23, 
    "mention": "Fig .", 
    "pid": 0, 
    "senid": 13, 
    "sent": "Conduction into the left pulmonary veins was still present because of the gap at the bottom of the LIPV -LRB- . Fig . 3 -RRB- .", 
    "start": 21.0, 
    "type": "Food"
}
{
    "end": 2, 
    "mention": "54-year-old", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 1.0, 
    "type": "Temporal_Concept"
}
{
    "end": 3, 
    "mention": "woman", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 2.0, 
    "type": "Population_Group"
}
{
    "end": 4, 
    "mention": "presented", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 3.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 6, 
    "mention": "giant", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 5.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 6, 
    "mention": "struma ", 
    "pid": 8, 
    "senid": 2, 
    "sent": "1", 
    "start": NaN, 
    "type": "Pathologic_Function"
}
{
    "end": 9, 
    "mention": "hyperthyroidism", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 8.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 11, 
    "mention": "unknown", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 10.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "duration ", 
    "pid": 13, 
    "senid": 2, 
    "sent": "1", 
    "start": NaN, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 14, 
    "mention": "palpitations", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 13.0, 
    "type": "Finding"
}
{
    "end": 17, 
    "mention": "dyspnoea .", 
    "pid": 2, 
    "senid": 1, 
    "sent": "A 54-year-old woman presented with giant struma , hyperthyroidism of unknown duration , palpitations and dyspnoea .", 
    "start": 15.0, 
    "type": "Sign_or_Symptom"
}
{
    "end": 2, 
    "mention": "39-year-old", 
    "pid": 1, 
    "senid": 1, 
    "sent": "A 39-year-old obese woman presented with influenza A -LRB- H1N1 -RRB- - related acute respiratory distress syndrome -LRB- ARDS -RRB- .", 
    "start": 1.0, 
    "type": "Temporal_Concept"
}
{
    "end": 3, 
    "mention": "obese", 
    "pid": 1, 
    "senid": 1, 
    "sent": "A 39-year-old obese woman presented with influenza A -LRB- H1N1 -RRB- - related acute respiratory distress syndrome -LRB- ARDS -RRB- .", 
    "start": 2.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 4, 
    "mention": "woman", 
    "pid": 1, 
    "senid": 1, 
    "sent": "A 39-year-old obese woman presented with influenza A -LRB- H1N1 -RRB- - related acute respiratory distress syndrome -LRB- ARDS -RRB- .", 
    "start": 3.0, 
    "type": "Population_Group"
}
{
    "end": 5, 
    "mention": "presented", 
    "pid": 1, 
    "senid": 1, 
    "sent": "A 39-year-old obese woman presented with influenza A -LRB- H1N1 -RRB- - related acute respiratory distress syndrome -LRB- ARDS -RRB- .", 
    "start": 4.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 17, 
    "mention": "acute respiratory distress syndrome", 
    "pid": 1, 
    "senid": 1, 
    "sent": "A 39-year-old obese woman presented with influenza A -LRB- H1N1 -RRB- - related acute respiratory distress syndrome -LRB- ARDS -RRB- .", 
    "start": 13.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 5, 
    "mention": "hydroxyzine overdose", 
    "pid": 3, 
    "senid": 3, 
    "sent": "Moreover , a hydroxyzine overdose was detected probably due to high posology , bile ducts obstruction , and liver impairment -LRB- rise in GPT -RRB- .", 
    "start": 3.0, 
    "type": "Injury_or_Poisoning"
}
{
    "end": 7, 
    "mention": "detected", 
    "pid": 3, 
    "senid": 3, 
    "sent": "Moreover , a hydroxyzine overdose was detected probably due to high posology , bile ducts obstruction , and liver impairment -LRB- rise in GPT -RRB- .", 
    "start": 6.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 8, 
    "mention": "probably", 
    "pid": 3, 
    "senid": 3, 
    "sent": "Moreover , a hydroxyzine overdose was detected probably due to high posology , bile ducts obstruction , and liver impairment -LRB- rise in GPT -RRB- .", 
    "start": 7.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 10, 
    "mention": "due to", 
    "pid": 3, 
    "senid": 3, 
    "sent": "Moreover , a hydroxyzine overdose was detected probably due to high posology , bile ducts obstruction , and liver impairment -LRB- rise in GPT -RRB- .", 
    "start": 8.0, 
    "type": "Functional_Concept"
}
{
    "end": 10, 
    "mention": "high posology ", 
    "pid": 13, 
    "senid": 3, 
    "sent": "3", 
    "start": NaN, 
    "type": "Quantitative_Concept"
}
{
    "end": 13, 
    "mention": "bile ducts obstruction ", 
    "pid": 17, 
    "senid": 3, 
    "sent": "3", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 20, 
    "mention": "liver impairment", 
    "pid": 3, 
    "senid": 3, 
    "sent": "Moreover , a hydroxyzine overdose was detected probably due to high posology , bile ducts obstruction , and liver impairment -LRB- rise in GPT -RRB- .", 
    "start": 18.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 2, 
    "mention": "patient", 
    "pid": 0, 
    "senid": 18, 
    "sent": "The patient was free of any tachycardia for 6 months .", 
    "start": 1.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 4, 
    "mention": "free", 
    "pid": 0, 
    "senid": 18, 
    "sent": "The patient was free of any tachycardia for 6 months .", 
    "start": 3.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 7, 
    "mention": "tachycardia", 
    "pid": 0, 
    "senid": 18, 
    "sent": "The patient was free of any tachycardia for 6 months .", 
    "start": 6.0, 
    "type": "Pathologic_Function"
}
{
    "end": 11, 
    "mention": "months .", 
    "pid": 0, 
    "senid": 18, 
    "sent": "The patient was free of any tachycardia for 6 months .", 
    "start": 9.0, 
    "type": "Temporal_Concept"
}
{
    "end": 2, 
    "mention": "electrode", 
    "pid": 0, 
    "senid": 6, 
    "sent": "Each electrode can be switched on and off separately .", 
    "start": 1.0, 
    "type": "Medical_Device"
}
{
    "end": 5, 
    "mention": "switched", 
    "pid": 0, 
    "senid": 6, 
    "sent": "Each electrode can be switched on and off separately .", 
    "start": 4.0, 
    "type": "Manufactured_Object"
}
{
    "end": 1, 
    "mention": "3 months ", 
    "pid": 4, 
    "senid": 0, 
    "sent": "2", 
    "start": NaN, 
    "type": "Temporal_Concept"
}
{
    "end": 6, 
    "mention": "presented", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 5.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 9, 
    "mention": "symptomatic", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 8.0, 
    "type": "Functional_Concept"
}
{
    "end": 13, 
    "mention": "cycle", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 12.0, 
    "type": "Temporal_Concept"
}
{
    "end": 14, 
    "mention": "length", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 13.0, 
    "type": "Research_Activity"
}
{
    "end": 17, 
    "mention": "ms", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 16.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 21, 
    "mention": "Fig .", 
    "pid": 0, 
    "senid": 2, 
    "sent": "After 3 months , he presented with a symptomatic LAMRT with a cycle length of 385 ms -LRB- . Fig . 1 -RRB- .", 
    "start": 19.0, 
    "type": "Food"
}
{
    "end": 2, 
    "mention": "only", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 1.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 3, 
    "mention": "one", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 2.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 4, 
    "mention": "published", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 3.0, 
    "type": "Occupational_Activity"
}
{
    "end": 5, 
    "mention": "clinical", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 4.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "case", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 8, 
    "mention": "hydroxyzine-induced", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 7.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 11, 
    "mention": "QT prolongation .", 
    "pid": 3, 
    "senid": 7, 
    "sent": "Theres only one published clinical case of hydroxyzine-induced QT prolongation .", 
    "start": 8.0, 
    "type": "Finding"
}
{
    "end": 4, 
    "mention": "automated external defibrillator", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 1.0, 
    "type": "Medical_Device"
}
{
    "end": 6, 
    "mention": "placed", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 5.0, 
    "type": "Spatial_Concept"
}
{
    "end": 9, 
    "mention": "received", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 8.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 10, 
    "mention": "appropriate", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 9.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "shock", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 10.0, 
    "type": "Pathologic_Function"
}
{
    "end": 15, 
    "mention": "transient", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 14.0, 
    "type": "Population_Group"
}
{
    "end": 17, 
    "mention": "CPR .", 
    "pid": 4, 
    "senid": 2, 
    "sent": "An automated external defibrillator was placed and he received appropriate shock as well as transient CPR .", 
    "start": 15.0, 
    "type": "Enzyme"
}
{
    "end": 2, 
    "mention": "diagnosis", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 1.0, 
    "type": "Finding"
}
{
    "end": 6, 
    "mention": "torsades de pointes", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 3.0, 
    "type": "Finding"
}
{
    "end": 8, 
    "mention": "associated with", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 6.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "prolonged QT interval", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 8.0, 
    "type": "Finding"
}
{
    "end": 13, 
    "mention": "part", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 12.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 15, 
    "mention": "due to", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 13.0, 
    "type": "Functional_Concept"
}
{
    "end": 16, 
    "mention": "cinacalcet-induced", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 15.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 17, 
    "mention": "severe", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 16.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 18, 
    "mention": "hypocalcemia", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 17.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 21, 
    "mention": "made .", 
    "pid": 4, 
    "senid": 14, 
    "sent": "The diagnosis of torsades de pointes associated with prolonged QT interval in part due to cinacalcet-induced severe hypocalcemia was made .", 
    "start": 19.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "chest X-ray", 
    "pid": 1, 
    "senid": 6, 
    "sent": "The chest X-ray -LRB- Fig . 1 -RRB- showed a malposi-tioned catheter in the left lung .", 
    "start": 1.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 6, 
    "mention": "Fig .", 
    "pid": 1, 
    "senid": 6, 
    "sent": "The chest X-ray -LRB- Fig . 1 -RRB- showed a malposi-tioned catheter in the left lung .", 
    "start": 4.0, 
    "type": "Food"
}
{
    "end": 9, 
    "mention": "showed", 
    "pid": 1, 
    "senid": 6, 
    "sent": "The chest X-ray -LRB- Fig . 1 -RRB- showed a malposi-tioned catheter in the left lung .", 
    "start": 8.0, 
    "type": "Animal"
}
{
    "end": 12, 
    "mention": "catheter", 
    "pid": 1, 
    "senid": 6, 
    "sent": "The chest X-ray -LRB- Fig . 1 -RRB- showed a malposi-tioned catheter in the left lung .", 
    "start": 11.0, 
    "type": "Medical_Device"
}
{
    "end": 17, 
    "mention": "left lung .", 
    "pid": 1, 
    "senid": 6, 
    "sent": "The chest X-ray -LRB- Fig . 1 -RRB- showed a malposi-tioned catheter in the left lung .", 
    "start": 14.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 1, 
    "mention": "Hypocalcemia", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 0.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 4, 
    "mention": "common", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 3.0, 
    "type": "Functional_Concept"
}
{
    "end": 4, 
    "mention": "adverse effect ", 
    "pid": 7, 
    "senid": 4, 
    "sent": "18", 
    "start": NaN, 
    "type": "Pathologic_Function"
}
{
    "end": 12, 
    "mention": "mitigated", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 11.0, 
    "type": "Phenomenon_or_Process"
}
{
    "end": 15, 
    "mention": "concurrent", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 14.0, 
    "type": "Temporal_Concept"
}
{
    "end": 17, 
    "mention": "use of", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 15.0, 
    "type": "Functional_Concept"
}
{
    "end": 18, 
    "mention": "calcium-based", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 17.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 21, 
    "mention": "phosphate binders .", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 18.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 19, 
    "mention": "calcium-based phosphate", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 17.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 21, 
    "mention": "binders .", 
    "pid": 4, 
    "senid": 18, 
    "sent": "Hypocalcemia is a common adverse effect , which can potentially be mitigated by the concurrent use of calcium-based phosphate binders .", 
    "start": 19.0, 
    "type": "Medical_Device"
}
{
    "end": 3, 
    "mention": "French", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 2.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 4, 
    "mention": "pharmacovigilance", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 3.0, 
    "type": "Research_Activity"
}
{
    "end": 4, 
    "mention": "database ", 
    "pid": 6, 
    "senid": 3, 
    "sent": "11", 
    "start": NaN, 
    "type": "Intellectual_Product"
}
{
    "end": 8, 
    "mention": "found", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 7.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 10, 
    "mention": "cases", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 9.0, 
    "type": "Functional_Concept"
}
{
    "end": 13, 
    "mention": "QT prolongation", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 11.0, 
    "type": "Finding"
}
{
    "end": 15, 
    "mention": "hydroxyzine", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 14.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 18, 
    "mention": "suspected", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 17.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 19, 
    "mention": "accountability", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 18.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 20, 
    "mention": "assumed", 
    "pid": 3, 
    "senid": 11, 
    "sent": "In the French pharmacovigilance database , we found 24 cases of QT prolongation mentioning hydroxyzine with a suspected accountability assumed in 7 cases .", 
    "start": 19.0, 
    "type": "Intellectual_Product"
}
{
    "end": 2, 
    "mention": "ECG", 
    "pid": 2, 
    "senid": 2, 
    "sent": "The ECG showed tachycardia atrial fibrillation .", 
    "start": 1.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 3, 
    "mention": "showed", 
    "pid": 2, 
    "senid": 2, 
    "sent": "The ECG showed tachycardia atrial fibrillation .", 
    "start": 2.0, 
    "type": "Animal"
}
{
    "end": 4, 
    "mention": "tachycardia", 
    "pid": 2, 
    "senid": 2, 
    "sent": "The ECG showed tachycardia atrial fibrillation .", 
    "start": 3.0, 
    "type": "Pathologic_Function"
}
{
    "end": 7, 
    "mention": "atrial fibrillation .", 
    "pid": 2, 
    "senid": 2, 
    "sent": "The ECG showed tachycardia atrial fibrillation .", 
    "start": 4.0, 
    "type": "Finding"
}
{
    "end": 3, 
    "mention": "reminds", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 2.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 5, 
    "mention": "recommended", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 4.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 7, 
    "mention": "hydroxyzines posology", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 5.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 9, 
    "mention": "respected ", 
    "pid": 11, 
    "senid": 3, 
    "sent": "15", 
    "start": NaN, 
    "type": "Social_Behavior"
}
{
    "end": 13, 
    "mention": "risk", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 12.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 16, 
    "mention": "QT prolongation", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 14.0, 
    "type": "Finding"
}
{
    "end": 18, 
    "mention": "syncope", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 17.0, 
    "type": "Amphibian"
}
{
    "end": 19, 
    "mention": "increases", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 18.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 22, 
    "mention": "case", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 21.0, 
    "type": "Functional_Concept"
}
{
    "end": 26, 
    "mention": "overdose .", 
    "pid": 3, 
    "senid": 15, 
    "sent": "It also reminds that recommended hydroxyzines posology must be respected , the risk of QT prolongation and syncope increases dramatically in case of an overdose .", 
    "start": 24.0, 
    "type": "Finding"
}
{
    "end": 2, 
    "mention": "patient", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 1.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 3, 
    "mention": "made", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 2.0, 
    "type": "Functional_Concept"
}
{
    "end": 5, 
    "mention": "full", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 4.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "recovery", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 5.0, 
    "type": "Organism_Function"
}
{
    "end": 9, 
    "mention": "discharged", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 8.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 10, 
    "mention": "home", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 9.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 12, 
    "mention": "months", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 11.0, 
    "type": "Temporal_Concept"
}
{
    "end": 15, 
    "mention": "hospital admission", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 13.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 18, 
    "mention": "neuro-logic", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 17.0, 
    "type": "Biomedical_Occupation_or_Discipline"
}
{
    "end": 20, 
    "mention": "cardiopulmonary", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 19.0, 
    "type": "Professional_or_Occupational_Group"
}
{
    "end": 22, 
    "mention": "sequelae .", 
    "pid": 1, 
    "senid": 10, 
    "sent": "The patient made a full recovery and was discharged home 2.5 months after hospital admission with no neuro-logic or cardiopulmonary sequelae .", 
    "start": 20.0, 
    "type": "Finding"
}
{
    "end": 2, 
    "mention": "patient", 
    "pid": 0, 
    "senid": 3, 
    "sent": "The patient was on amiodarone -LRB- 200 mg daily -RRB- .", 
    "start": 1.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 5, 
    "mention": "amiodarone", 
    "pid": 0, 
    "senid": 3, 
    "sent": "The patient was on amiodarone -LRB- 200 mg daily -RRB- .", 
    "start": 4.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 8, 
    "mention": "mg", 
    "pid": 0, 
    "senid": 3, 
    "sent": "The patient was on amiodarone -LRB- 200 mg daily -RRB- .", 
    "start": 7.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 62, 
    "mention": "activation", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 61.0, 
    "type": "Activity"
}
{
    "end": 3, 
    "mention": "map", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 2.0, 
    "type": "Manufactured_Object"
}
{
    "end": 4, 
    "mention": "revealed", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 3.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 9, 
    "mention": "exit", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 8.0, 
    "type": "Spatial_Concept"
}
{
    "end": 25, 
    "mention": "superior pulmonary vein", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 22.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 31, 
    "mention": "entrance", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 30.0, 
    "type": "Spatial_Concept"
}
{
    "end": 34, 
    "mention": "bottom", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 33.0, 
    "type": "Spatial_Concept"
}
{
    "end": 40, 
    "mention": "left inferior pulmonary vein", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 36.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 46, 
    "mention": "Fig .", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 44.0, 
    "type": "Food"
}
{
    "end": 50, 
    "mention": "placing", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 49.0, 
    "type": "Spatial_Concept"
}
{
    "end": 53, 
    "mention": "catheter", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 52.0, 
    "type": "Medical_Device"
}
{
    "end": 55, 
    "mention": "ostium of the LSPV ", 
    "pid": 60, 
    "senid": 0, 
    "sent": "9", 
    "start": NaN, 
    "type": "Body_Space_or_Junction"
}
{
    "end": 63, 
    "mention": "sequence", 
    "pid": 0, 
    "senid": 9, 
    "sent": "The activation map revealed an LAMRT with its exit to the left atrium -LRB- LA -RRB- at the roof of the left superior pulmonary vein -LRB- LSPV -RRB- and its entrance at the bottom of the left inferior pulmonary vein -LRB- LIPV ; . Fig . 2 -RRB- By placing the nMarq catheter at the ostium of the LSPV , the activation sequence could be nicely depicted .", 
    "start": 62.0, 
    "type": "Intellectual_Product"
}
{
    "end": 1, 
    "mention": "Conclusion", 
    "pid": 0, 
    "senid": 19, 
    "sent": "Conclusion The reentrant circuit of this LAMRT could be nicely depicted using the nMarq catheter .", 
    "start": 0.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 12, 
    "mention": "using", 
    "pid": 0, 
    "senid": 19, 
    "sent": "Conclusion The reentrant circuit of this LAMRT could be nicely depicted using the nMarq catheter .", 
    "start": 11.0, 
    "type": "Functional_Concept"
}
{
    "end": 16, 
    "mention": "catheter .", 
    "pid": 0, 
    "senid": 19, 
    "sent": "Conclusion The reentrant circuit of this LAMRT could be nicely depicted using the nMarq catheter .", 
    "start": 14.0, 
    "type": "Medical_Device"
}
{
    "end": 1, 
    "mention": "Hypocalcemia", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 0.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 2, 
    "mention": "further", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 1.0, 
    "type": "Spatial_Concept"
}
{
    "end": 3, 
    "mention": "increases", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 2.0, 
    "type": "Functional_Concept"
}
{
    "end": 4, 
    "mention": "risk", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 3.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 7, 
    "mention": "development", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 9, 
    "mention": "early", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 8.0, 
    "type": "Temporal_Concept"
}
{
    "end": 12, 
    "mention": "patients", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 11.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 13, 
    "mention": "arrhythmia", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 12.0, 
    "type": "Finding"
}
{
    "end": 15, 
    "mention": "not", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 14.0, 
    "type": "Functional_Concept"
}
{
    "end": 16, 
    "mention": "resolve", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 15.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 21, 
    "mention": "serum calcium level", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 18.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 21, 
    "mention": "normalized ", 
    "pid": 23, 
    "senid": 4, 
    "sent": "22", 
    "start": NaN, 
    "type": "Research_Activity"
}
{
    "end": 26, 
    "mention": "electrolytes", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 25.0, 
    "type": "Inorganic_Chemical"
}
{
    "end": 29, 
    "mention": "replaced .", 
    "pid": 4, 
    "senid": 22, 
    "sent": "Hypocalcemia further increases risk by potentiating development of early after depolarizations.Our patients arrhythmia did not resolve until his serum calcium level normalized , and other electrolytes were replaced .", 
    "start": 27.0, 
    "type": "Functional_Concept"
}
{
    "end": 2, 
    "mention": "ab-lation", 
    "pid": 0, 
    "senid": 14, 
    "sent": "After ab-lation at this site , the lateral pulmonary veins were isolated .", 
    "start": 1.0, 
    "type": "Eukaryote"
}
{
    "end": 4, 
    "mention": "site ", 
    "pid": 6, 
    "senid": 0, 
    "sent": "14", 
    "start": NaN, 
    "type": "Body_Location_or_Region"
}
{
    "end": 8, 
    "mention": "lateral", 
    "pid": 0, 
    "senid": 14, 
    "sent": "After ab-lation at this site , the lateral pulmonary veins were isolated .", 
    "start": 7.0, 
    "type": "Spatial_Concept"
}
{
    "end": 10, 
    "mention": "pulmonary veins", 
    "pid": 0, 
    "senid": 14, 
    "sent": "After ab-lation at this site , the lateral pulmonary veins were isolated .", 
    "start": 8.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 13, 
    "mention": "isolated .", 
    "pid": 0, 
    "senid": 14, 
    "sent": "After ab-lation at this site , the lateral pulmonary veins were isolated .", 
    "start": 11.0, 
    "type": "Functional_Concept"
}
{
    "end": 1, 
    "mention": "day 2 ", 
    "pid": 4, 
    "senid": 1, 
    "sent": "2", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 5, 
    "mention": "refractory", 
    "pid": 1, 
    "senid": 2, 
    "sent": "At day 2 , refractory hypoxemia ensued and veno-venous extracorporeal membrane oxygenation -LRB- ECMO -RRB- was initiated .", 
    "start": 4.0, 
    "type": "Functional_Concept"
}
{
    "end": 6, 
    "mention": "hypoxemia", 
    "pid": 1, 
    "senid": 2, 
    "sent": "At day 2 , refractory hypoxemia ensued and veno-venous extracorporeal membrane oxygenation -LRB- ECMO -RRB- was initiated .", 
    "start": 5.0, 
    "type": "Finding"
}
{
    "end": 9, 
    "mention": "veno-venous", 
    "pid": 1, 
    "senid": 2, 
    "sent": "At day 2 , refractory hypoxemia ensued and veno-venous extracorporeal membrane oxygenation -LRB- ECMO -RRB- was initiated .", 
    "start": 8.0, 
    "type": "Spatial_Concept"
}
{
    "end": 12, 
    "mention": "extracorporeal membrane oxygenation", 
    "pid": 1, 
    "senid": 2, 
    "sent": "At day 2 , refractory hypoxemia ensued and veno-venous extracorporeal membrane oxygenation -LRB- ECMO -RRB- was initiated .", 
    "start": 9.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 18, 
    "mention": "initiated .", 
    "pid": 1, 
    "senid": 2, 
    "sent": "At day 2 , refractory hypoxemia ensued and veno-venous extracorporeal membrane oxygenation -LRB- ECMO -RRB- was initiated .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 1, 
    "mention": "PVI ", 
    "pid": 3, 
    "senid": 0, 
    "sent": "7", 
    "start": NaN, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 5, 
    "mention": "antral", 
    "pid": 0, 
    "senid": 7, 
    "sent": "For PVI , an antral ablation -LRB- outside the PV -RRB- was performed .", 
    "start": 4.0, 
    "type": "Organic_Chemical"
}
{
    "end": 6, 
    "mention": "ablation", 
    "pid": 0, 
    "senid": 7, 
    "sent": "For PVI , an antral ablation -LRB- outside the PV -RRB- was performed .", 
    "start": 5.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 8, 
    "mention": "outside", 
    "pid": 0, 
    "senid": 7, 
    "sent": "For PVI , an antral ablation -LRB- outside the PV -RRB- was performed .", 
    "start": 7.0, 
    "type": "Spatial_Concept"
}
{
    "end": 14, 
    "mention": "performed .", 
    "pid": 0, 
    "senid": 7, 
    "sent": "For PVI , an antral ablation -LRB- outside the PV -RRB- was performed .", 
    "start": 12.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "brought", 
    "pid": 4, 
    "senid": 3, 
    "sent": "He was brought to our emergency department for further management .", 
    "start": 2.0, 
    "type": "Functional_Concept"
}
{
    "end": 7, 
    "mention": "emergency department", 
    "pid": 4, 
    "senid": 3, 
    "sent": "He was brought to our emergency department for further management .", 
    "start": 5.0, 
    "type": "Health_Care_Related_Organization"
}
{
    "end": 9, 
    "mention": "further", 
    "pid": 4, 
    "senid": 3, 
    "sent": "He was brought to our emergency department for further management .", 
    "start": 8.0, 
    "type": "Spatial_Concept"
}
{
    "end": 11, 
    "mention": "management .", 
    "pid": 4, 
    "senid": 3, 
    "sent": "He was brought to our emergency department for further management .", 
    "start": 9.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 1, 
    "mention": "1", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 0.0, 
    "type": "Finding"
}
{
    "end": 3, 
    "mention": "Turbo field-echo", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 1.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 7, 
    "mention": "inversion", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 6.0, 
    "type": "Spatial_Concept"
}
{
    "end": 8, 
    "mention": "recovery", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 7.0, 
    "type": "Activity"
}
{
    "end": 12, 
    "mention": "sequences", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 11.0, 
    "type": "Intellectual_Product"
}
{
    "end": 14, 
    "mention": "vertical", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 13.0, 
    "type": "Spatial_Concept"
}
{
    "end": 19, 
    "mention": "horizontal", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 18.0, 
    "type": "Spatial_Concept"
}
{
    "end": 24, 
    "mention": "long axis", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 22.0, 
    "type": "Spatial_Concept"
}
{
    "end": 26, 
    "mention": "10 min", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 24.0, 
    "type": "Temporal_Concept"
}
{
    "end": 33, 
    "mention": "intravenous gadolinium-based contrast agent administration :", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 27.0, 
    "type": "Spatial_Concept"
}
{
    "end": 31, 
    "mention": "gadolinium-based contrast agent", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 28.0, 
    "type": "Indicator__Reagent__or_Diagnostic_Aid"
}
{
    "end": 35, 
    "mention": "healthy", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 34.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 36, 
    "mention": "basal", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 35.0, 
    "type": "Spatial_Concept"
}
{
    "end": 39, 
    "mention": "myocardium", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 38.0, 
    "type": "Tissue"
}
{
    "end": 40, 
    "mention": "shows", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 39.0, 
    "type": "Animal"
}
{
    "end": 42, 
    "mention": "prolonged", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 41.0, 
    "type": "Temporal_Concept"
}
{
    "end": 64, 
    "mention": "gadolinium", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 63.0, 
    "type": "Element__Ion__or_Isotope"
}
{
    "end": 44, 
    "mention": "retention", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 43.0, 
    "type": "Mental_Process"
}
{
    "end": 49, 
    "mention": "black", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 48.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 56, 
    "mention": "transmural", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 55.0, 
    "type": "Functional_Concept"
}
{
    "end": 57, 
    "mention": "scar", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 56.0, 
    "type": "Pathologic_Function"
}
{
    "end": 60, 
    "mention": "apical", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 59.0, 
    "type": "Spatial_Concept"
}
{
    "end": 61, 
    "mention": "segments", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 60.0, 
    "type": "Spatial_Concept"
}
{
    "end": 62, 
    "mention": "retains", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 61.0, 
    "type": "Functional_Concept"
}
{
    "end": 68, 
    "mention": "bright", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 67.0, 
    "type": "Finding"
}
{
    "end": 69, 
    "mention": "appearance", 
    "pid": 2, 
    "senid": 5, 
    "sent": "1 Turbo field-echo -LRB- TFE -RRB- inversion recovery -LRB- IR -RRB- sequences in vertical -LRB- a -RRB- and horizontal -LRB- b -RRB- long axis 10 min after intravenous gadolinium-based contrast agent administration : the healthy basal and midventricular myocardium shows no prolonged gadolinium retention and is depicted in black -LRB- arrowheads -RRB- , whereas the transmural scar in the apical segments retains the gadolinium and has a bright appearance -LRB- arrows -RRB- .", 
    "start": 68.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 2, 
    "mention": "case", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 1.0, 
    "type": "Functional_Concept"
}
{
    "end": 4, 
    "mention": "recurrent", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 3.0, 
    "type": "Temporal_Concept"
}
{
    "end": 5, 
    "mention": "syncope", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 4.0, 
    "type": "Amphibian"
}
{
    "end": 7, 
    "mention": "hydroxyzine", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 6.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 8, 
    "mention": "treatment", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 7.0, 
    "type": "Research_Activity"
}
{
    "end": 10, 
    "mention": "usual", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 9.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "posology", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 10.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 14, 
    "mention": "34-year-old", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 13.0, 
    "type": "Temporal_Concept"
}
{
    "end": 15, 
    "mention": "woman", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 14.0, 
    "type": "Population_Group"
}
{
    "end": 16, 
    "mention": "presenting", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 15.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 18, 
    "mention": "hERG", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 17.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 20, 
    "mention": "mutation .", 
    "pid": 3, 
    "senid": 8, 
    "sent": "This case describes recurrent syncope during hydroxyzine treatment at usual posology in a 34-year-old woman presenting a hERG mutation .", 
    "start": 18.0, 
    "type": "Genetic_Function"
}
{
    "end": 2, 
    "mention": "Three weeks", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 0.0, 
    "type": "Temporal_Concept"
}
{
    "end": 4, 
    "mention": "prior to", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 2.0, 
    "type": "Temporal_Concept"
}
{
    "end": 4, 
    "mention": "admission ", 
    "pid": 6, 
    "senid": 4, 
    "sent": "10", 
    "start": NaN, 
    "type": "Health_Care_Activity"
}
{
    "end": 8, 
    "mention": "cinacalcet", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 7.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 9, 
    "mention": "dose", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 8.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 11, 
    "mention": "increased", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 10.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 13, 
    "mention": "60", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 12.0, 
    "type": "Finding"
}
{
    "end": 15, 
    "mention": "90", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 14.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 17, 
    "mention": "daily", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 16.0, 
    "type": "Temporal_Concept"
}
{
    "end": 18, 
    "mention": "to 90 mg daily due", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 13.0, 
    "type": "Functional_Concept"
}
{
    "end": 22, 
    "mention": "iPTH level", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 20.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 25, 
    "mention": "mg daily due to an iPTH level of 85.6 pmol/L", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 15.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 27, 
    "mention": "calcium", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 26.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 29, 
    "mention": "2.11", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 28.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 34, 
    "mention": "phosphorus", 
    "pid": 4, 
    "senid": 10, 
    "sent": "Three weeks prior to admission , his cinacalcet dose was increased from 60 to 90 mg daily due to an iPTH level of 85.6 pmol/L -LRB- calcium was 2.11 mmol / L and phosphorus was 2.26 mmol/L -RRB- .", 
    "start": 33.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 2, 
    "mention": "Fig .", 
    "pid": 1, 
    "senid": 11, 
    "sent": "Fig .", 
    "start": 0.0, 
    "type": "Food"
}
{
    "end": 1, 
    "mention": "Cetirizine", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 0.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 4, 
    "mention": "hydroxyzines", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 3.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 5, 
    "mention": "major", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 4.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "active", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 8, 
    "mention": "metabolite ;", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 6.0, 
    "type": "Biologically_Active_Substance"
}
{
    "end": 12, 
    "mention": "blood", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 11.0, 
    "type": "Body_Substance"
}
{
    "end": 13, 
    "mention": "level", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 12.0, 
    "type": "Classification"
}
{
    "end": 14, 
    "mention": "dosage", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 13.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 16, 
    "mention": "not", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 15.0, 
    "type": "Functional_Concept"
}
{
    "end": 18, 
    "mention": "performed .", 
    "pid": 3, 
    "senid": 4, 
    "sent": "Cetirizine is the hydroxyzines major active metabolite ; unfortunately , its blood level dosage was not performed .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 2, 
    "mention": "publish", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 1.0, 
    "type": "Occupational_Activity"
}
{
    "end": 5, 
    "mention": "first", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 4.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "clinical", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 5.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 7, 
    "mention": "case", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 11, 
    "mention": "QT prolongation", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 9.0, 
    "type": "Finding"
}
{
    "end": 14, 
    "mention": "drug dosage", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 12.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 16, 
    "mention": "data .", 
    "pid": 3, 
    "senid": 12, 
    "sent": "We publish here the first clinical case of hydroxyzineassociated QT prolongation with drug dosage data .", 
    "start": 14.0, 
    "type": "Eukaryote"
}
{
    "end": 1, 
    "mention": "Echocardiography", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 0.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 2, 
    "mention": "revealed", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 1.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 2, 
    "mention": "dilatation of the left ventricle ", 
    "pid": 8, 
    "senid": 2, 
    "sent": "3", 
    "start": NaN, 
    "type": "Congenital_Abnormality"
}
{
    "end": 9, 
    "mention": "highly", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 8.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 10, 
    "mention": "reduced", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 9.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "systolic", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 10.0, 
    "type": "Temporal_Concept"
}
{
    "end": 12, 
    "mention": "function", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 11.0, 
    "type": "Functional_Concept"
}
{
    "end": 14, 
    "mention": "diffuse", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 13.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 16, 
    "mention": "hypokinesia .", 
    "pid": 2, 
    "senid": 3, 
    "sent": "Echocardiography revealed dilatation of the left ventricle , highly reduced systolic function and diffuse hypokinesia .", 
    "start": 14.0, 
    "type": "Sign_or_Symptom"
}
{
    "end": 1, 
    "mention": "Once", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 0.0, 
    "type": "Temporal_Concept"
}
{
    "end": 5, 
    "mention": "total body calcium", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 2.0, 
    "type": "Element__Ion__or_Isotope"
}
{
    "end": 4, 
    "mention": "body", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 3.0, 
    "type": "Anatomical_Structure"
}
{
    "end": 4, 
    "mention": "total body", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 2.0, 
    "type": "Fully_Formed_Anatomical_Structure"
}
{
    "end": 5, 
    "mention": "calcium", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 4.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 6, 
    "mention": "replaced ", 
    "pid": 8, 
    "senid": 4, 
    "sent": "15", 
    "start": NaN, 
    "type": "Functional_Concept"
}
{
    "end": 11, 
    "mention": "QT interval", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 9.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 12, 
    "mention": "normalized", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 11.0, 
    "type": "Research_Activity"
}
{
    "end": 15, 
    "mention": "electrocardiogram", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 14.0, 
    "type": "Intellectual_Product"
}
{
    "end": 18, 
    "mention": "further", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 17.0, 
    "type": "Spatial_Concept"
}
{
    "end": 19, 
    "mention": "ar-rhythmias", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 18.0, 
    "type": "Finding"
}
{
    "end": 22, 
    "mention": "observed .", 
    "pid": 4, 
    "senid": 15, 
    "sent": "Once his total body calcium was replaced , the QT interval normalized on his electrocardiogram and no further ar-rhythmias were observed .", 
    "start": 20.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "considering", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 2.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 5, 
    "mention": "large", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 4.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 7, 
    "mention": "use of", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 8, 
    "mention": "molecule ", 
    "pid": 10, 
    "senid": 3, 
    "sent": "16", 
    "start": NaN, 
    "type": "Substance"
}
{
    "end": 12, 
    "mention": "recurrence", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 11.0, 
    "type": "Pathologic_Function"
}
{
    "end": 14, 
    "mention": "hydroxyzine-induced", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 13.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 16, 
    "mention": "QT prolongation", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 14.0, 
    "type": "Finding"
}
{
    "end": 18, 
    "mention": "probably", 
    "pid": 3, 
    "senid": 16, 
    "sent": "Finally , considering the large use of the molecule , the recurrence of hydroxyzine-induced QT prolongation is probably underestimated .", 
    "start": 17.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 2, 
    "mention": "Cardiac arrest", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 0.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 5, 
    "mention": "emergent", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 4.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 6, 
    "mention": "sternotomy", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 5.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 8, 
    "mention": "performed", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 7.0, 
    "type": "Functional_Concept"
}
{
    "end": 10, 
    "mention": "ECMO-assisted", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 9.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 12, 
    "mention": "cardiopulmonary resuscitation", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 10.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 15, 
    "mention": "femoral artery", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 13.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 16, 
    "mention": "cannu-lation", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 15.0, 
    "type": "Eukaryote"
}
{
    "end": 18, 
    "mention": "venous-venous-arterial", 
    "pid": 1, 
    "senid": 7, 
    "sent": "Cardiac arrest ensued and emergent sternotomy was performed under ECMO-assisted cardiopulmonary resuscitation after femoral artery cannu-lation -LRB- venous-venous-arterial ECMO -RRB- .", 
    "start": 17.0, 
    "type": "Spatial_Concept"
}
{
    "end": 2, 
    "mention": "PVI-redo", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 1.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 4, 
    "mention": "performed", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 3.0, 
    "type": "Functional_Concept"
}
{
    "end": 5, 
    "mention": "using", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 4.0, 
    "type": "Functional_Concept"
}
{
    "end": 7, 
    "mention": "novel", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 6.0, 
    "type": "Intellectual_Product"
}
{
    "end": 8, 
    "mention": "circular", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 7.0, 
    "type": "Spatial_Concept"
}
{
    "end": 9, 
    "mention": "mapping", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 8.0, 
    "type": "Activity"
}
{
    "end": 12, 
    "mention": "catheter", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 11.0, 
    "type": "Medical_Device"
}
{
    "end": 19, 
    "mention": "Diamond", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 18.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 22, 
    "mention": "Calif.", 
    "pid": 0, 
    "senid": 4, 
    "sent": "A PVI-redo was performed using a novel circular mapping and abla-tion catheter -LRB- nMarq , Biosense Webster , Diamond Bar , Calif. , USA -RRB- .", 
    "start": 21.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 1, 
    "mention": "Symptomatic", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 0.0, 
    "type": "Functional_Concept"
}
{
    "end": 2, 
    "mention": "hypocalcemia", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 1.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 3, 
    "mention": "induced", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 2.0, 
    "type": "Functional_Concept"
}
{
    "end": 5, 
    "mention": "cinacalcet", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 4.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 6, 
    "mention": "rare ", 
    "pid": 8, 
    "senid": 4, 
    "sent": "19", 
    "start": NaN, 
    "type": "Qualitative_Concept"
}
{
    "end": 12, 
    "mention": "OPTIMA", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 11.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 12, 
    "mention": "study ", 
    "pid": 14, 
    "senid": 4, 
    "sent": "19", 
    "start": NaN, 
    "type": "Research_Activity"
}
{
    "end": 15, 
    "mention": "only", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 14.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 18, 
    "mention": "patients", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 17.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 19, 
    "mention": "presented", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 18.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 24, 
    "mention": "serum calcium level", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 21.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 28, 
    "mention": "mg/dL", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 27.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 30, 
    "mention": "1.87", 
    "pid": 4, 
    "senid": 19, 
    "sent": "Symptomatic hypocalcemia induced by cinacalcet is rare , and in the OPTIMA study , only 5 of patients presented with a serum calcium level less than 7.5 mg/dL -LRB- 1.87 mmol/L -RRB- .", 
    "start": 29.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 3, 
    "mention": "septal ablation", 
    "pid": 0, 
    "senid": 15, 
    "sent": "The septal ablation line showed gaps in the anteriorinferior part , which were successfully closed .", 
    "start": 1.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 4, 
    "mention": "line", 
    "pid": 0, 
    "senid": 15, 
    "sent": "The septal ablation line showed gaps in the anteriorinferior part , which were successfully closed .", 
    "start": 3.0, 
    "type": "Medical_Device"
}
{
    "end": 5, 
    "mention": "showed", 
    "pid": 0, 
    "senid": 15, 
    "sent": "The septal ablation line showed gaps in the anteriorinferior part , which were successfully closed .", 
    "start": 4.0, 
    "type": "Animal"
}
{
    "end": 6, 
    "mention": "gaps", 
    "pid": 0, 
    "senid": 15, 
    "sent": "The septal ablation line showed gaps in the anteriorinferior part , which were successfully closed .", 
    "start": 5.0, 
    "type": "Spatial_Concept"
}
{
    "end": 9, 
    "mention": "part ", 
    "pid": 11, 
    "senid": 0, 
    "sent": "15", 
    "start": NaN, 
    "type": "Quantitative_Concept"
}
{
    "end": 16, 
    "mention": "closed .", 
    "pid": 0, 
    "senid": 15, 
    "sent": "The septal ablation line showed gaps in the anteriorinferior part , which were successfully closed .", 
    "start": 14.0, 
    "type": "Functional_Concept"
}
{
    "end": 1, 
    "mention": "Successful", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 0.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 2, 
    "mention": "ablation", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 1.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 5, 
    "mention": "exit", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 4.0, 
    "type": "Spatial_Concept"
}
{
    "end": 7, 
    "mention": "entrance", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 6.0, 
    "type": "Spatial_Concept"
}
{
    "end": 8, 
    "mention": "site", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 7.0, 
    "type": "Body_Location_or_Region"
}
{
    "end": 11, 
    "mention": "performed", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 10.0, 
    "type": "Functional_Concept"
}
{
    "end": 13, 
    "mention": "moving", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 12.0, 
    "type": "Organism_Function"
}
{
    "end": 16, 
    "mention": "catheter .", 
    "pid": 0, 
    "senid": 20, 
    "sent": "Successful ablation at the exit and entrance site could be performed without moving the catheter .", 
    "start": 14.0, 
    "type": "Medical_Device"
}
{
    "end": 2, 
    "mention": "knowledge ", 
    "pid": 4, 
    "senid": 4, 
    "sent": "23", 
    "start": NaN, 
    "type": "Intellectual_Product"
}
{
    "end": 8, 
    "mention": "one", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 7.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 11, 
    "mention": "first", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 10.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 12, 
    "mention": "reported", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 11.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 13, 
    "mention": "cases", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 12.0, 
    "type": "Functional_Concept"
}
{
    "end": 15, 
    "mention": "cinacalcet-induced", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 14.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 16, 
    "mention": "hypocalcemia", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 15.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 13, 
    "mention": "reported cases", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 11.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 18, 
    "mention": "resulting in", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 21, 
    "mention": "torsades de pointes", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 18.0, 
    "type": "Finding"
}
{
    "end": 25, 
    "mention": "cardiac arrest .", 
    "pid": 4, 
    "senid": 23, 
    "sent": "To our knowledge , this may be one of the first reported cases of cinacalcet-induced hypocalcemia resulting in torsades de pointes and cardiac arrest .", 
    "start": 22.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 1, 
    "mention": "1", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 0.0, 
    "type": "Finding"
}
{
    "end": 3, 
    "mention": "Chest X-ray", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 1.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 4, 
    "mention": "showing", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 3.0, 
    "type": "Animal"
}
{
    "end": 6, 
    "mention": "malpositioned", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 5.0, 
    "type": "Spatial_Concept"
}
{
    "end": 7, 
    "mention": "left", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 11, 
    "mention": "subclavian central venous catheter", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 7.0, 
    "type": "Finding"
}
{
    "end": 12, 
    "mention": "Intensive", 
    "pid": 1, 
    "senid": 12, 
    "sent": "1 Chest X-ray showing the malpositioned left subclavian central venous catheter Intensive", 
    "start": 11.0, 
    "type": "Mental_Process"
}
{
    "end": 2, 
    "mention": "home", 
    "pid": 4, 
    "senid": 11, 
    "sent": "Other home medications included sevelamer carbonate , nifedipine XL , and metoprolol succinate .", 
    "start": 1.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 3, 
    "mention": "medications", 
    "pid": 4, 
    "senid": 11, 
    "sent": "Other home medications included sevelamer carbonate , nifedipine XL , and metoprolol succinate .", 
    "start": 2.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 4, 
    "mention": "included", 
    "pid": 4, 
    "senid": 11, 
    "sent": "Other home medications included sevelamer carbonate , nifedipine XL , and metoprolol succinate .", 
    "start": 3.0, 
    "type": "Functional_Concept"
}
{
    "end": 4, 
    "mention": "sevelamer carbonate ", 
    "pid": 7, 
    "senid": 4, 
    "sent": "11", 
    "start": NaN, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 8, 
    "mention": "nifedipine", 
    "pid": 4, 
    "senid": 11, 
    "sent": "Other home medications included sevelamer carbonate , nifedipine XL , and metoprolol succinate .", 
    "start": 7.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 8, 
    "mention": "XL ", 
    "pid": 10, 
    "senid": 4, 
    "sent": "11", 
    "start": NaN, 
    "type": "Geographic_Area"
}
{
    "end": 14, 
    "mention": "metoprolol succinate .", 
    "pid": 4, 
    "senid": 11, 
    "sent": "Other home medications included sevelamer carbonate , nifedipine XL , and metoprolol succinate .", 
    "start": 11.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 2, 
    "mention": "history", 
    "pid": 4, 
    "senid": 4, 
    "sent": "His history included hypertension , hepatitis C infection , human immunodeficiency virus infection , anemia , and secondary hyperparathyroidism .", 
    "start": 1.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "included", 
    "pid": 4, 
    "senid": 4, 
    "sent": "His history included hypertension , hepatitis C infection , human immunodeficiency virus infection , anemia , and secondary hyperparathyroidism .", 
    "start": 2.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "hypertension ", 
    "pid": 5, 
    "senid": 4, 
    "sent": "4", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 5, 
    "mention": "hepatitis C infection ", 
    "pid": 9, 
    "senid": 4, 
    "sent": "4", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 13, 
    "mention": "human immunodeficiency virus infection", 
    "pid": 4, 
    "senid": 4, 
    "sent": "His history included hypertension , hepatitis C infection , human immunodeficiency virus infection , anemia , and secondary hyperparathyroidism .", 
    "start": 9.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 14, 
    "mention": "anemia ", 
    "pid": 16, 
    "senid": 4, 
    "sent": "4", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 20, 
    "mention": "secondary hyperparathyroidism .", 
    "pid": 4, 
    "senid": 4, 
    "sent": "His history included hypertension , hepatitis C infection , human immunodeficiency virus infection , anemia , and secondary hyperparathyroidism .", 
    "start": 17.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 2, 
    "mention": "finding", 
    "pid": 2, 
    "senid": 6, 
    "sent": "Auxiliary finding of bilateral pleural effusions -LRB- asterisk -RRB-", 
    "start": 1.0, 
    "type": "Finding"
}
{
    "end": 6, 
    "mention": "bilateral pleural effusions", 
    "pid": 2, 
    "senid": 6, 
    "sent": "Auxiliary finding of bilateral pleural effusions -LRB- asterisk -RRB-", 
    "start": 3.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 1, 
    "mention": "Pacing", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 0.0, 
    "type": "Individual_Behavior"
}
{
    "end": 4, 
    "mention": "roof", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 3.0, 
    "type": "Manufactured_Object"
}
{
    "end": 7, 
    "mention": "LSPV", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 6.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 8, 
    "mention": "showed", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 7.0, 
    "type": "Animal"
}
{
    "end": 12, 
    "mention": "PPI", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 11.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 18, 
    "mention": "similar", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 17.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 19, 
    "mention": "p-wave", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 18.0, 
    "type": "Organism_Attribute"
}
{
    "end": 20, 
    "mention": "morphology", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 19.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 21, 
    "mention": "compared", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 20.0, 
    "type": "Activity"
}
{
    "end": 25, 
    "mention": "tachy-cardia .", 
    "pid": 0, 
    "senid": 10, 
    "sent": "Pacing from the roof of the LSPV showed perfect entrainment -LRB- PPI +8 ms -RRB- and a similar p-wave morphology compared to the tachy-cardia .", 
    "start": 23.0, 
    "type": "Intellectual_Product"
}
{
    "end": 4, 
    "mention": "combination", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 3.0, 
    "type": "Finding"
}
{
    "end": 7, 
    "mention": "hydroxyzine overdose", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 5.0, 
    "type": "Injury_or_Poisoning"
}
{
    "end": 9, 
    "mention": "transient", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 8.0, 
    "type": "Population_Group"
}
{
    "end": 11, 
    "mention": "renal failure", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 9.0, 
    "type": "Pathologic_Function"
}
{
    "end": 14, 
    "mention": "lead", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 13.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 15, 
    "mention": "to", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 14.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 16, 
    "mention": "cetirizine", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 15.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 18, 
    "mention": "accumulation .", 
    "pid": 3, 
    "senid": 5, 
    "sent": "We suppose that combination of hydroxyzine overdose and transient renal failure could have lead to cetirizine accumulation .", 
    "start": 16.0, 
    "type": "Finding"
}
{
    "end": 2, 
    "mention": "day", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 1.0, 
    "type": "Temporal_Concept"
}
{
    "end": 5, 
    "mention": "venous", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 4.0, 
    "type": "Spatial_Concept"
}
{
    "end": 7, 
    "mention": "catheter-related infection", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 5.0, 
    "type": "Pathologic_Function"
}
{
    "end": 9, 
    "mention": "suspected", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 8.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 14, 
    "mention": "left subclavian venous", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 11.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 15, 
    "mention": "catheter", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 14.0, 
    "type": "Medical_Device"
}
{
    "end": 17, 
    "mention": "inserted", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 16.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 18, 
    "mention": "using", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 17.0, 
    "type": "Functional_Concept"
}
{
    "end": 19, 
    "mention": "Seldinger technique ", 
    "pid": 22, 
    "senid": 1, 
    "sent": "3", 
    "start": NaN, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 24, 
    "mention": "blood", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 23.0, 
    "type": "Body_Substance"
}
{
    "end": 27, 
    "mention": "freely", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 26.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 28, 
    "mention": "aspirated", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 27.0, 
    "type": "Pathologic_Function"
}
{
    "end": 36, 
    "mention": "insertion of the catheter .", 
    "pid": 1, 
    "senid": 3, 
    "sent": "At day 15 , venous catheter-related infection was suspected and a left subclavian venous catheter was inserted using the Seldinger technique , with blood that was freely aspirated before and after insertion of the catheter .", 
    "start": 31.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 2, 
    "mention": "single", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 1.0, 
    "type": "Population_Group"
}
{
    "end": 3, 
    "mention": "transseptal", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 2.0, 
    "type": "Spatial_Concept"
}
{
    "end": 4, 
    "mention": "puncture", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 3.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 9, 
    "mention": "map", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 8.0, 
    "type": "Manufactured_Object"
}
{
    "end": 13, 
    "mention": "left atrium", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 11.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 15, 
    "mention": "acquired", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 14.0, 
    "type": "Temporal_Concept"
}
{
    "end": 16, 
    "mention": "using", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 15.0, 
    "type": "Functional_Concept"
}
{
    "end": 20, 
    "mention": "catheter .", 
    "pid": 0, 
    "senid": 8, 
    "sent": "After single transseptal puncture , a CARTO 3 map of the left atrium was acquired using the nMarq catheter .", 
    "start": 18.0, 
    "type": "Medical_Device"
}
{
    "end": 1, 
    "mention": "hERG", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 0.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 2, 
    "mention": "gene", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 1.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 3, 
    "mention": "codes", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 2.0, 
    "type": "Occupational_Activity"
}
{
    "end": 6, 
    "mention": "subunit", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 5.0, 
    "type": "Amino_Acid__Peptide__or_Protein"
}
{
    "end": 10, 
    "mention": "potassium channel", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 8.0, 
    "type": "Amino_Acid__Peptide__or_Protein"
}
{
    "end": 12, 
    "mention": "I", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 11.0, 
    "type": "Amino_Acid__Peptide__or_Protein"
}
{
    "end": 13, 
    "mention": "Kr", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 12.0, 
    "type": "Geographic_Area"
}
{
    "end": 20, 
    "mention": "ventricular repolarization .", 
    "pid": 3, 
    "senid": 9, 
    "sent": "hERG gene codes for the subunit of a potassium channel -LRB- I Kr -RRB- implicated in the ventricular repolarization .", 
    "start": 17.0, 
    "type": "Organ_or_Tissue_Function"
}
{
    "end": 2, 
    "mention": "Phosphate binders", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 0.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 5, 
    "mention": "vitamin D", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 3.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 6, 
    "mention": "sterols", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 5.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 11, 
    "mention": "management", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 10.0, 
    "type": "Occupational_Activity"
}
{
    "end": 14, 
    "mention": "secondary hyperparathyroidism", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 12.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 16, 
    "mention": "patients", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 15.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 19, 
    "mention": "ESRD .", 
    "pid": 4, 
    "senid": 16, 
    "sent": "Phosphate binders and vitamin D sterols are the mainstay of management for secondary hyperparathyroidism in patients with ESRD .", 
    "start": 17.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 3, 
    "mention": "end", 
    "pid": 0, 
    "senid": 16, 
    "sent": "At the end of the procedure there was no in-ducible tachycardia .", 
    "start": 2.0, 
    "type": "Spatial_Concept"
}
{
    "end": 6, 
    "mention": "procedure", 
    "pid": 0, 
    "senid": 16, 
    "sent": "At the end of the procedure there was no in-ducible tachycardia .", 
    "start": 5.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 12, 
    "mention": "tachycardia .", 
    "pid": 0, 
    "senid": 16, 
    "sent": "At the end of the procedure there was no in-ducible tachycardia .", 
    "start": 10.0, 
    "type": "Pathologic_Function"
}
{
    "end": 1, 
    "mention": "Initial", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 0.0, 
    "type": "Temporal_Concept"
}
{
    "end": 3, 
    "mention": "laboratory data", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 1.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 4, 
    "mention": "revealed", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 3.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "uncorrected", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 5.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 18, 
    "mention": "calcium", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 17.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 9, 
    "mention": "1.65", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 8.0, 
    "type": "Finding"
}
{
    "end": 59, 
    "mention": "mmol/L", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 58.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 57, 
    "mention": "normal", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 56.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 13, 
    "mention": "2.12.55", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 12.0, 
    "type": "Intellectual_Product"
}
{
    "end": 18, 
    "mention": "ionized calcium", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 16.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 20, 
    "mention": "0.71", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 19.0, 
    "type": "Finding"
}
{
    "end": 29, 
    "mention": "potassium", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 28.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 40, 
    "mention": "magnesium", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 39.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 52, 
    "mention": "phosphorus", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 51.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 54, 
    "mention": "0.97", 
    "pid": 4, 
    "senid": 6, 
    "sent": "Initial laboratory data revealed an uncorrected calcium of 1.65 mmol/L -LRB- normal 2.12.55 mmol/L -RRB- , ionized calcium of 0.71 mmol/L -LRB- normal 1.12 1.32 mmol/L -RRB- , potassium of 3.2 mmol/L -LRB- normal 3.5 5.1 mmol/L -RRB- , magnesium of 0.61 mmol/L -LRB- normal 0.66 0.95 mmol/L -RRB- , and phosphorus of 0.97 mmol/L -LRB- normal 0.811.45 mmol/L -RRB- .", 
    "start": 53.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 2, 
    "mention": "Pulmonary artery", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 0.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 3, 
    "mention": "perforation", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 2.0, 
    "type": "Finding"
}
{
    "end": 6, 
    "mention": "Fig .", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 4.0, 
    "type": "Food"
}
{
    "end": 10, 
    "mention": "hemopericardium", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 9.0, 
    "type": "Pathologic_Function"
}
{
    "end": 12, 
    "mention": "then", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 11.0, 
    "type": "Temporal_Concept"
}
{
    "end": 13, 
    "mention": "surgically", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 12.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 14, 
    "mention": "repaired", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 13.0, 
    "type": "Functional_Concept"
}
{
    "end": 16, 
    "mention": "catheter", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 15.0, 
    "type": "Medical_Device"
}
{
    "end": 18, 
    "mention": "withdrawal .", 
    "pid": 1, 
    "senid": 8, 
    "sent": "Pulmonary artery perforation -LRB- Fig . 2 -RRB- and hemopericardium were then surgically repaired after catheter withdrawal .", 
    "start": 16.0, 
    "type": "Finding"
}
{
    "end": 2, 
    "mention": "association", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 1.0, 
    "type": "Social_Behavior"
}
{
    "end": 3, 
    "mention": "hydroxyzine ", 
    "pid": 5, 
    "senid": 3, 
    "sent": "13", 
    "start": NaN, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 7, 
    "mention": "high posology ", 
    "pid": 10, 
    "senid": 3, 
    "sent": "13", 
    "start": NaN, 
    "type": "Quantitative_Concept"
}
{
    "end": 12, 
    "mention": "others", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 11.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 14, 
    "mention": "well-known", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 13.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 16, 
    "mention": "risks", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 15.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 17, 
    "mention": "factors", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 19, 
    "mention": "including", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 18.0, 
    "type": "Functional_Concept"
}
{
    "end": 20, 
    "mention": "hypokalemia", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 19.0, 
    "type": "Finding"
}
{
    "end": 25, 
    "mention": "induce", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 24.0, 
    "type": "Functional_Concept"
}
{
    "end": 27, 
    "mention": "QT prolongation", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 25.0, 
    "type": "Finding"
}
{
    "end": 29, 
    "mention": "lifethreatening", 
    "pid": 3, 
    "senid": 13, 
    "sent": "The association of hydroxyzine , especially at high posology , and others already well-known TdP risks factors -LRB- including hypokalemia and bradycardia -RRB- could induce QT prolongation and lifethreatening TdP .", 
    "start": 28.0, 
    "type": "Finding"
}
{
    "end": 1, 
    "mention": "Information", 
    "pid": 3, 
    "senid": 17, 
    "sent": "Information must be given to clinician .", 
    "start": 0.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 4, 
    "mention": "given", 
    "pid": 3, 
    "senid": 17, 
    "sent": "Information must be given to clinician .", 
    "start": 3.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 7, 
    "mention": "clinician .", 
    "pid": 3, 
    "senid": 17, 
    "sent": "Information must be given to clinician .", 
    "start": 5.0, 
    "type": "Professional_or_Occupational_Group"
}
{
    "end": 1, 
    "mention": "arrival ", 
    "pid": 3, 
    "senid": 4, 
    "sent": "5", 
    "start": NaN, 
    "type": "Activity"
}
{
    "end": 7, 
    "mention": "hemodynamically stable", 
    "pid": 4, 
    "senid": 5, 
    "sent": "On arrival , he was hemodynamically stable and euvolemic on exam .", 
    "start": 5.0, 
    "type": "Finding"
}
{
    "end": 9, 
    "mention": "euvolemic", 
    "pid": 4, 
    "senid": 5, 
    "sent": "On arrival , he was hemodynamically stable and euvolemic on exam .", 
    "start": 8.0, 
    "type": "Finding"
}
{
    "end": 12, 
    "mention": "exam .", 
    "pid": 4, 
    "senid": 5, 
    "sent": "On arrival , he was hemodynamically stable and euvolemic on exam .", 
    "start": 10.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 5, 
    "mention": "acute circulatory shock", 
    "pid": 1, 
    "senid": 4, 
    "sent": "However , acute circulatory shock was observed shortly afterwards .", 
    "start": 2.0, 
    "type": "Pathologic_Function"
}
{
    "end": 7, 
    "mention": "observed", 
    "pid": 1, 
    "senid": 4, 
    "sent": "However , acute circulatory shock was observed shortly afterwards .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "cetirizine", 
    "pid": 3, 
    "senid": 6, 
    "sent": "However , cetirizine seems to be safe regarding ventricular repolarization , even at supratherapeutic dose .", 
    "start": 2.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 5, 
    "mention": "to", 
    "pid": 3, 
    "senid": 6, 
    "sent": "However , cetirizine seems to be safe regarding ventricular repolarization , even at supratherapeutic dose .", 
    "start": 4.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 8, 
    "mention": "ventricular repolarization ", 
    "pid": 11, 
    "senid": 3, 
    "sent": "6", 
    "start": NaN, 
    "type": "Organ_or_Tissue_Function"
}
{
    "end": 16, 
    "mention": "dose .", 
    "pid": 3, 
    "senid": 6, 
    "sent": "However , cetirizine seems to be safe regarding ventricular repolarization , even at supratherapeutic dose .", 
    "start": 14.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 2, 
    "mention": "recommended", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 1.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 4, 
    "mention": "pharmaceutical company ", 
    "pid": 7, 
    "senid": 4, 
    "sent": "24", 
    "start": NaN, 
    "type": "Health_Care_Related_Organization"
}
{
    "end": 9, 
    "mention": "serum calcium", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 7.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 13, 
    "mention": "ionized calcium levels", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 10.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 16, 
    "mention": "measured", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 15.0, 
    "type": "Diagnostic_Procedure"
}
{
    "end": 19, 
    "mention": "week", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 18.0, 
    "type": "Temporal_Concept"
}
{
    "end": 21, 
    "mention": "initiation", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 20.0, 
    "type": "Functional_Concept"
}
{
    "end": 24, 
    "mention": "dose adjustment", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 22.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 27, 
    "mention": "cinacalcet .", 
    "pid": 4, 
    "senid": 24, 
    "sent": "As recommended by the pharmaceutical company , serum calcium and ionized calcium levels should be measured within 1 week after initiation or dose adjustment of cinacalcet .", 
    "start": 25.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 0, 
    "mention": "On admission ", 
    "pid": 3, 
    "senid": 4, 
    "sent": "12", 
    "start": NaN, 
    "type": "Temporal_Concept"
}
{
    "end": 4, 
    "mention": "cinacalcet", 
    "pid": 4, 
    "senid": 12, 
    "sent": "On admission , cinacalcet was stopped , and magnesium , potassium , and calcium were administered .", 
    "start": 3.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 5, 
    "mention": "stopped ", 
    "pid": 7, 
    "senid": 4, 
    "sent": "12", 
    "start": NaN, 
    "type": "Qualitative_Concept"
}
{
    "end": 9, 
    "mention": "magnesium", 
    "pid": 4, 
    "senid": 12, 
    "sent": "On admission , cinacalcet was stopped , and magnesium , potassium , and calcium were administered .", 
    "start": 8.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 10, 
    "mention": "potassium ", 
    "pid": 12, 
    "senid": 4, 
    "sent": "12", 
    "start": NaN, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 14, 
    "mention": "calcium", 
    "pid": 4, 
    "senid": 12, 
    "sent": "On admission , cinacalcet was stopped , and magnesium , potassium , and calcium were administered .", 
    "start": 13.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 17, 
    "mention": "administered .", 
    "pid": 4, 
    "senid": 12, 
    "sent": "On admission , cinacalcet was stopped , and magnesium , potassium , and calcium were administered .", 
    "start": 15.0, 
    "type": "Functional_Concept"
}
{
    "end": 1, 
    "mention": "Ablation", 
    "pid": 0, 
    "senid": 11, 
    "sent": "Ablation at this site terminated the LAMRT .", 
    "start": 0.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 4, 
    "mention": "site", 
    "pid": 0, 
    "senid": 11, 
    "sent": "Ablation at this site terminated the LAMRT .", 
    "start": 3.0, 
    "type": "Body_Location_or_Region"
}
{
    "end": 5, 
    "mention": "terminated", 
    "pid": 0, 
    "senid": 11, 
    "sent": "Ablation at this site terminated the LAMRT .", 
    "start": 4.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 3, 
    "mention": "last", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 2.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 3, 
    "mention": "decades ", 
    "pid": 5, 
    "senid": 3, 
    "sent": "1", 
    "start": NaN, 
    "type": "Quantitative_Concept"
}
{
    "end": 6, 
    "mention": "number", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 5.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 8, 
    "mention": "drugs", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 7.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 10, 
    "mention": "withdrawn", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 9.0, 
    "type": "Activity"
}
{
    "end": 12, 
    "mention": "due to", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 10.0, 
    "type": "Functional_Concept"
}
{
    "end": 13, 
    "mention": "cases", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 12.0, 
    "type": "Functional_Concept"
}
{
    "end": 17, 
    "mention": "leading", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 18, 
    "mention": "to", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 17.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 22, 
    "mention": "assessment of drug", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 19.0, 
    "type": "Research_Activity"
}
{
    "end": 25, 
    "mention": "QT interval .", 
    "pid": 3, 
    "senid": 1, 
    "sent": "In the last decades , number of drugs were withdrawn due to cases of TdP , leading to intensify assessment of drug QT interval .", 
    "start": 22.0, 
    "type": "Clinical_Attribute"
}
{
    "end": 0, 
    "mention": "Torsades de pointes ", 
    "pid": 4, 
    "senid": 4, 
    "sent": "20", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 5, 
    "mention": "polymorphic form of ventricular tachycardia ", 
    "pid": 11, 
    "senid": 4, 
    "sent": "20", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 7, 
    "mention": "form", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 6.0, 
    "type": "Manufactured_Object"
}
{
    "end": 13, 
    "mention": "seen", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 12.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 15, 
    "mention": "patients", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 14.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 17, 
    "mention": "prolonged", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 16.0, 
    "type": "Temporal_Concept"
}
{
    "end": 18, 
    "mention": "cardiomyocyte", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 17.0, 
    "type": "Cell"
}
{
    "end": 23, 
    "mention": "exhibited", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 22.0, 
    "type": "Intellectual_Product"
}
{
    "end": 25, 
    "mention": "electrocardiogram", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 24.0, 
    "type": "Intellectual_Product"
}
{
    "end": 28, 
    "mention": "long QT", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 26.0, 
    "type": "Finding"
}
{
    "end": 30, 
    "mention": "intervals .", 
    "pid": 4, 
    "senid": 20, 
    "sent": "Torsades de pointes , a polymorphic form of ventricular tachycardia , is seen in patients with prolonged cardiomyocyte repolarization , which is exhibited on electrocardiogram by long QT intervals .", 
    "start": 28.0, 
    "type": "Temporal_Concept"
}
{
    "end": 1, 
    "mention": "Cinacalcet", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 0.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 3, 
    "mention": "recently", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 2.0, 
    "type": "Temporal_Concept"
}
{
    "end": 4, 
    "mention": "introduced", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 3.0, 
    "type": "Functional_Concept"
}
{
    "end": 7, 
    "mention": "alternative", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 6.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 7, 
    "mention": "option ", 
    "pid": 9, 
    "senid": 4, 
    "sent": "17", 
    "start": NaN, 
    "type": "Functional_Concept"
}
{
    "end": 10, 
    "mention": "working", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 9.0, 
    "type": "Occupational_Activity"
}
{
    "end": 15, 
    "mention": "calcium sensing receptor", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 12.0, 
    "type": "Amino_Acid__Peptide__or_Protein"
}
{
    "end": 17, 
    "mention": "enhancing", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 16.0, 
    "type": "Activity"
}
{
    "end": 20, 
    "mention": "sensitivity to", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 18.0, 
    "type": "Functional_Concept"
}
{
    "end": 21, 
    "mention": "extracellular", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 20.0, 
    "type": "Cell_Component"
}
{
    "end": 22, 
    "mention": "calcium", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 21.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 25, 
    "mention": "inhibiting", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 24.0, 
    "type": "Activity"
}
{
    "end": 28, 
    "mention": "release .", 
    "pid": 4, 
    "senid": 17, 
    "sent": "Cinacalcet was recently introduced as an alternative option , working via the calcium sensing receptor by enhancing its sensitivity to extracellular calcium and thereby inhibiting PTH release .", 
    "start": 26.0, 
    "type": "Functional_Concept"
}
{
    "end": 3, 
    "mention": "factors", 
    "pid": 4, 
    "senid": 13, 
    "sent": "No other factors capable of inducing hypocalcemia were identified .", 
    "start": 2.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 4, 
    "mention": "capable", 
    "pid": 4, 
    "senid": 13, 
    "sent": "No other factors capable of inducing hypocalcemia were identified .", 
    "start": 3.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 6, 
    "mention": "inducing", 
    "pid": 4, 
    "senid": 13, 
    "sent": "No other factors capable of inducing hypocalcemia were identified .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 7, 
    "mention": "hypocalcemia", 
    "pid": 4, 
    "senid": 13, 
    "sent": "No other factors capable of inducing hypocalcemia were identified .", 
    "start": 6.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 10, 
    "mention": "identified .", 
    "pid": 4, 
    "senid": 13, 
    "sent": "No other factors capable of inducing hypocalcemia were identified .", 
    "start": 8.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 2, 
    "mention": "present", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 1.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 3, 
    "mention": "work", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 2.0, 
    "type": "Occupational_Activity"
}
{
    "end": 6, 
    "mention": "recent", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 5.0, 
    "type": "Temporal_Concept"
}
{
    "end": 7, 
    "mention": "addition", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 9, 
    "mention": "hydroxyzine", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 8.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 14, 
    "mention": "list of drugs", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 11.0, 
    "type": "Intellectual_Product"
}
{
    "end": 16, 
    "mention": "conditional", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 15.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 17, 
    "mention": "risk", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 16.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 21, 
    "mention": "drugs", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 20.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 22, 
    "mention": "to", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 21.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 26, 
    "mention": "patients", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 25.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 32, 
    "mention": "congenital long QT syndrome .", 
    "pid": 3, 
    "senid": 14, 
    "sent": "The present work underlines the recent addition of hydroxyzine to the list of drugs with conditional risk of TdP and drugs to be avoided by patients with congenital long QT syndrome .", 
    "start": 27.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 11, 
    "mention": "less than", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 9.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 12, 
    "mention": "0.03", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 11.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 13, 
    "mention": "lU/ml", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 12.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 15, 
    "mention": "physiological", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 14.0, 
    "type": "Functional_Concept"
}
{
    "end": 16, 
    "mention": "range", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 15.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 24, 
    "mention": "free triiodothyronine", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 22.0, 
    "type": "Hormone"
}
{
    "end": 33, 
    "mention": "pg/ml", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 32.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 32, 
    "mention": "2.304.20", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 31.0, 
    "type": "Classification"
}
{
    "end": 37, 
    "mention": "free thyroxine", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 35.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 41, 
    "mention": "amounted", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 40.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 44, 
    "mention": "Fig .", 
    "pid": 2, 
    "senid": 4, 
    "sent": "Serum thyroid stimulating hormone -LRB- TSH -RRB- levels were less than 0.03 lU/ml -LRB- physiological range 0.554.78 lU / ml -RRB- , free triiodothyronine -LRB- fT3 -RRB- was 7.32 pg/ml -LRB- 2.304.20 pg/ml -RRB- and free thyroxine -LRB- fT4 -RRB- amounted to Fig .", 
    "start": 42.0, 
    "type": "Food"
}
{
    "end": 2, 
    "mention": "44-year-old", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 1.0, 
    "type": "Temporal_Concept"
}
{
    "end": 3, 
    "mention": "male", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 2.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 5, 
    "mention": "ESRD", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 4.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 9, 
    "mention": "usual", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 8.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 12, 
    "mention": "state of health", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 9.0, 
    "type": "Finding"
}
{
    "end": 15, 
    "mention": "day", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 14.0, 
    "type": "Temporal_Concept"
}
{
    "end": 17, 
    "mention": "hospitalization", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 16.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 21, 
    "mention": "unresponsive", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 20.0, 
    "type": "Finding"
}
{
    "end": 23, 
    "mention": "pulseless", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 22.0, 
    "type": "Finding"
}
{
    "end": 26, 
    "mention": "hemodialysis .", 
    "pid": 4, 
    "senid": 1, 
    "sent": "A 44-year-old male with ESRD was in his usual state of health until the day of hospitalization when he became unresponsive and pulseless during hemodialysis .", 
    "start": 24.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 5, 
    "mention": "shown", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 4.0, 
    "type": "Animal"
}
{
    "end": 7, 
    "mention": "hydroxyzine", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 6.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 12, 
    "mention": "blocking", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 11.0, 
    "type": "Mental_or_Behavioral_Dysfunction"
}
{
    "end": 13, 
    "mention": "hERG", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 12.0, 
    "type": "Gene_or_Genome"
}
{
    "end": 14, 
    "mention": "channels", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 13.0, 
    "type": "Spatial_Concept"
}
{
    "end": 19, 
    "mention": "action potential", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 17.0, 
    "type": "Cell_Function"
}
{
    "end": 19, 
    "mention": "duration ", 
    "pid": 21, 
    "senid": 3, 
    "sent": "10", 
    "start": NaN, 
    "type": "Temporal_Concept"
}
{
    "end": 23, 
    "mention": "inducing", 
    "pid": 3, 
    "senid": 10, 
    "sent": "Experimentally , it was shown that hydroxyzine could be proarrhythmic by blocking hERG channels and therefore prolonging action potential duration , thus inducing TdP .", 
    "start": 22.0, 
    "type": "Functional_Concept"
}
{
    "end": 2, 
    "mention": "exit", 
    "pid": 0, 
    "senid": 12, 
    "sent": "The exit to the LA was blocked .", 
    "start": 1.0, 
    "type": "Spatial_Concept"
}
{
    "end": 5, 
    "mention": "LA", 
    "pid": 0, 
    "senid": 12, 
    "sent": "The exit to the LA was blocked .", 
    "start": 4.0, 
    "type": "Body_Part__Organ__or_Organ_Component"
}
{
    "end": 8, 
    "mention": "blocked .", 
    "pid": 0, 
    "senid": 12, 
    "sent": "The exit to the LA was blocked .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 0, 
    "mention": "Hypocalcemia ", 
    "pid": 2, 
    "senid": 4, 
    "sent": "21", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 2, 
    "mention": "hypokalemia ", 
    "pid": 4, 
    "senid": 4, 
    "sent": "21", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 6, 
    "mention": "hypomagnesemia", 
    "pid": 4, 
    "senid": 21, 
    "sent": "Hypocalcemia , hypokalemia , and hypomagnesemia increase risk of torsades de pointes by prolonging repolarization .", 
    "start": 5.0, 
    "type": "Finding"
}
{
    "end": 7, 
    "mention": "increase", 
    "pid": 4, 
    "senid": 21, 
    "sent": "Hypocalcemia , hypokalemia , and hypomagnesemia increase risk of torsades de pointes by prolonging repolarization .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 8, 
    "mention": "risk", 
    "pid": 4, 
    "senid": 21, 
    "sent": "Hypocalcemia , hypokalemia , and hypomagnesemia increase risk of torsades de pointes by prolonging repolarization .", 
    "start": 7.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 12, 
    "mention": "torsades de pointes", 
    "pid": 4, 
    "senid": 21, 
    "sent": "Hypocalcemia , hypokalemia , and hypomagnesemia increase risk of torsades de pointes by prolonging repolarization .", 
    "start": 9.0, 
    "type": "Finding"
}
{
    "end": 1, 
    "mention": "Once", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 0.0, 
    "type": "Temporal_Concept"
}
{
    "end": 4, 
    "mention": "maintenance dose", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 2.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 6, 
    "mention": "established ", 
    "pid": 8, 
    "senid": 4, 
    "sent": "25", 
    "start": NaN, 
    "type": "Qualitative_Concept"
}
{
    "end": 9, 
    "mention": "monthly", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 8.0, 
    "type": "Temporal_Concept"
}
{
    "end": 10, 
    "mention": "monitoring", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 9.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 13, 
    "mention": "serum calcium", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 11.0, 
    "type": "Laboratory_Procedure"
}
{
    "end": 19, 
    "mention": "importance", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 18.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 21, 
    "mention": "adherence", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 20.0, 
    "type": "Functional_Concept"
}
{
    "end": 23, 
    "mention": "oral", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 22.0, 
    "type": "Spatial_Concept"
}
{
    "end": 25, 
    "mention": "calcium supplementation", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 23.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 27, 
    "mention": "as needed", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 25.0, 
    "type": "Temporal_Concept"
}
{
    "end": 30, 
    "mention": "stressed", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 29.0, 
    "type": "Finding"
}
{
    "end": 34, 
    "mention": "patients .", 
    "pid": 4, 
    "senid": 25, 
    "sent": "Once a maintenance dose has been established , monthly monitoring of serum calcium is warranted , and the importance of adherence to oral calcium supplementation as needed should be stressed with all patients .", 
    "start": 32.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 2, 
    "mention": "case ", 
    "pid": 4, 
    "senid": 3, 
    "sent": "2", 
    "start": NaN, 
    "type": "Functional_Concept"
}
{
    "end": 5, 
    "mention": "hydroxyzine", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 4.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 10, 
    "mention": "only", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 9.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 11, 
    "mention": "identified as the only drug", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 6.0, 
    "type": "Laboratory_or_Test_Result"
}
{
    "end": 12, 
    "mention": "able", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 11.0, 
    "type": "Finding"
}
{
    "end": 13, 
    "mention": "to", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 12.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 14, 
    "mention": "induce", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 13.0, 
    "type": "Functional_Concept"
}
{
    "end": 17, 
    "mention": "QTc interval prolongation", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 14.0, 
    "type": "Finding"
}
{
    "end": 20, 
    "mention": "patients", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 19.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 21, 
    "mention": "active", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 20.0, 
    "type": "Functional_Concept"
}
{
    "end": 23, 
    "mention": "medication .", 
    "pid": 3, 
    "senid": 2, 
    "sent": "In our case , hydroxyzine was identified as the only drug able to induce QTc interval prolongation in the patients active medication .", 
    "start": 21.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 1, 
    "mention": "Initial", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 0.0, 
    "type": "Temporal_Concept"
}
{
    "end": 2, 
    "mention": "electrocardiogram", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 1.0, 
    "type": "Intellectual_Product"
}
{
    "end": 3, 
    "mention": "showed", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 2.0, 
    "type": "Animal"
}
{
    "end": 6, 
    "mention": "sinus rhythm", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 4.0, 
    "type": "Finding"
}
{
    "end": 11, 
    "mention": "prolonged QT interval", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 8.0, 
    "type": "Finding"
}
{
    "end": 13, 
    "mention": "diffuse", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 12.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 14, 
    "mention": "T-wave", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 13.0, 
    "type": "Finding"
}
{
    "end": 15, 
    "mention": "changes", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 14.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 33, 
    "mention": "Fig .", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 31.0, 
    "type": "Food"
}
{
    "end": 23, 
    "mention": "minutes ", 
    "pid": 25, 
    "senid": 4, 
    "sent": "7", 
    "start": NaN, 
    "type": "Temporal_Concept"
}
{
    "end": 30, 
    "mention": "torsades de pointes", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 27.0, 
    "type": "Finding"
}
{
    "end": 39, 
    "mention": "unresponsive .", 
    "pid": 4, 
    "senid": 7, 
    "sent": "Initial electrocardiogram showed a sinus rhythm with a prolonged QT interval and diffuse T-wave changes -LRB- Fig . 1a -RRB- , but in minutes , he developed torsades de pointes -LRB- Fig . 1b -RRB- and became unresponsive .", 
    "start": 37.0, 
    "type": "Finding"
}
{
    "end": 4, 
    "mention": "resuscitated", 
    "pid": 4, 
    "senid": 8, 
    "sent": "He was again resuscitated and transferred to the intensive care unit .", 
    "start": 3.0, 
    "type": "Finding"
}
{
    "end": 6, 
    "mention": "transferred", 
    "pid": 4, 
    "senid": 8, 
    "sent": "He was again resuscitated and transferred to the intensive care unit .", 
    "start": 5.0, 
    "type": "Functional_Concept"
}
{
    "end": 12, 
    "mention": "intensive care unit .", 
    "pid": 4, 
    "senid": 8, 
    "sent": "He was again resuscitated and transferred to the intensive care unit .", 
    "start": 8.0, 
    "type": "Manufactured_Object"
}
{
    "end": 1, 
    "mention": "Treatment", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 0.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 5, 
    "mention": "secondary hyperparathyroidism", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 3.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 8, 
    "mention": "initiated", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 7.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 9, 
    "mention": "3", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 8.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 10, 
    "mention": "years", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 9.0, 
    "type": "Temporal_Concept"
}
{
    "end": 11, 
    "mention": "prior", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 10.0, 
    "type": "Temporal_Concept"
}
{
    "end": 28, 
    "mention": "pmol/L", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 27.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 25, 
    "mention": "normal", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 24.0, 
    "type": "Finding"
}
{
    "end": 31, 
    "mention": "included", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 30.0, 
    "type": "Functional_Concept"
}
{
    "end": 32, 
    "mention": "paricalcitol", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 31.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 34, 
    "mention": "hemodialysis", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 33.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 36, 
    "mention": "daily", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 35.0, 
    "type": "Temporal_Concept"
}
{
    "end": 38, 
    "mention": "cinacalcet .", 
    "pid": 4, 
    "senid": 9, 
    "sent": "Treatment of his secondary hyperparathyroidism had been initiated 3 years prior when his intact parathyroid hormone -LRB- iPTH -RRB- level was 117 pmol/L -LRB- normal 24.2 66.1 pmol/L -RRB- and included paricalcitol with hemodialysis and daily cinacalcet .", 
    "start": 36.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 1, 
    "mention": "Abnormalities", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 0.0, 
    "type": "Congenital_Abnormality"
}
{
    "end": 4, 
    "mention": "serum potassium", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 2.0, 
    "type": "Laboratory_or_Test_Result"
}
{
    "end": 11, 
    "mention": "EKG", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 10.0, 
    "type": "Finding"
}
{
    "end": 29, 
    "mention": "showing", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 28.0, 
    "type": "Animal"
}
{
    "end": 13, 
    "mention": "diffuse", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 12.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 16, 
    "mention": "T wave abnormalities", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 13.0, 
    "type": "Finding"
}
{
    "end": 21, 
    "mention": "QT interval prolongation ;", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 17.0, 
    "type": "Finding"
}
{
    "end": 19, 
    "mention": "interval", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 18.0, 
    "type": "Intellectual_Product"
}
{
    "end": 24, 
    "mention": "cardiac monitor", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 22.0, 
    "type": "Medical_Device"
}
{
    "end": 25, 
    "mention": "strips", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 24.0, 
    "type": "Medical_Device"
}
{
    "end": 28, 
    "mention": "patient", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 27.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 32, 
    "mention": "polymorphic ventricular tachycardia", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 29.0, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 34, 
    "mention": "consistent with", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 32.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 37, 
    "mention": "torsades de pointes", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 34.0, 
    "type": "Finding"
}
{
    "end": 41, 
    "mention": "risk", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 40.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 42, 
    "mention": "arrhythmias ", 
    "pid": 44, 
    "senid": 4, 
    "sent": "26", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 46, 
    "mention": "monthly", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 45.0, 
    "type": "Temporal_Concept"
}
{
    "end": 49, 
    "mention": "monitoring of electrolytes", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 46.0, 
    "type": "Therapeutic_or_Preventive_Procedure"
}
{
    "end": 50, 
    "mention": "to", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 49.0, 
    "type": "Geographic_Area"
}
{
    "end": 51, 
    "mention": "ensure", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 50.0, 
    "type": "Food"
}
{
    "end": 56, 
    "mention": "normal serum levels of potassium", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 51.0, 
    "type": "Finding"
}
{
    "end": 62, 
    "mention": "recommended .", 
    "pid": 4, 
    "senid": 26, 
    "sent": "Abnormalities in serum potassium and magnesium -LRB- b -RRB- a EKG showing diffuse T wave abnormalities and QT interval prolongation ; b cardiac monitor strips from this patient showing polymorphic ventricular tachycardia consistent with torsades de pointes might potentiate the risk for arrhythmias , and monthly monitoring of electrolytes to ensure normal serum levels of potassium and magnesium is also recommended .", 
    "start": 60.0, 
    "type": "Idea_or_Concept"
}
{
    "end": 1, 
    "mention": "Cinacalcet", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 0.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 4, 
    "mention": "used", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 3.0, 
    "type": "Finding"
}
{
    "end": 7, 
    "mention": "patients", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 6.0, 
    "type": "Patient_or_Disabled_Group"
}
{
    "end": 9, 
    "mention": "known", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 8.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 11, 
    "mention": "risk factors", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 9.0, 
    "type": "Intellectual_Product"
}
{
    "end": 12, 
    "mention": "hypocalcemia ", 
    "pid": 14, 
    "senid": 4, 
    "sent": "27", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 17, 
    "mention": "history", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 16.0, 
    "type": "Functional_Concept"
}
{
    "end": 18, 
    "mention": "QT prolongation ", 
    "pid": 21, 
    "senid": 4, 
    "sent": "27", 
    "start": NaN, 
    "type": "Finding"
}
{
    "end": 24, 
    "mention": "concurrent", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 23.0, 
    "type": "Temporal_Concept"
}
{
    "end": 26, 
    "mention": "use of", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 24.0, 
    "type": "Functional_Concept"
}
{
    "end": 28, 
    "mention": "QT", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 27.0, 
    "type": "Quantitative_Concept"
}
{
    "end": 31, 
    "mention": "agents .", 
    "pid": 4, 
    "senid": 27, 
    "sent": "Cinacalcet should be used cautiously in patients with known risk factors for hypocalcemia , with a history of QT prolongation , and with concurrent use of other QT prolonging agents .", 
    "start": 29.0, 
    "type": "Pharmacologic_Substance"
}
{
    "end": 1, 
    "mention": "Authors", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 0.0, 
    "type": "Professional_or_Occupational_Group"
}
{
    "end": 2, 
    "mention": "contribution", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 1.0, 
    "type": "Activity"
}
{
    "end": 6, 
    "mention": "access", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 5.0, 
    "type": "Spatial_Concept"
}
{
    "end": 9, 
    "mention": "data", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 8.0, 
    "type": "Medical_Device"
}
{
    "end": 12, 
    "mention": "role", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 11.0, 
    "type": "Conceptual_Entity"
}
{
    "end": 14, 
    "mention": "writing", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 13.0, 
    "type": "Occupation_or_Discipline"
}
{
    "end": 17, 
    "mention": "manuscript .", 
    "pid": 4, 
    "senid": 28, 
    "sent": "Authors contribution All authors had access to the data and a role in writing the manuscript .", 
    "start": 15.0, 
    "type": "Intellectual_Product"
}
{
    "end": 2, 
    "mention": "report", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 1.0, 
    "type": "Health_Care_Activity"
}
{
    "end": 4, 
    "mention": "images", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 3.0, 
    "type": "Intellectual_Product"
}
{
    "end": 7, 
    "mention": "case", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 6.0, 
    "type": "Functional_Concept"
}
{
    "end": 10, 
    "mention": "atrial flutter", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 8.0, 
    "type": "Laboratory_or_Test_Result"
}
{
    "end": 12, 
    "mention": "2:1", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 11.0, 
    "type": "Finding"
}
{
    "end": 18, 
    "mention": "2:1 conduction pattern in a 3 year-old", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 11.0, 
    "type": "Age_Group"
}
{
    "end": 14, 
    "mention": "conduction pattern", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 12.0, 
    "type": "Laboratory_or_Test_Result"
}
{
    "end": 19, 
    "mention": "male", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 18.0, 
    "type": "Qualitative_Concept"
}
{
    "end": 20, 
    "mention": "d-TGA ", 
    "pid": 22, 
    "senid": 5, 
    "sent": "1", 
    "start": NaN, 
    "type": "Disease_or_Syndrome"
}
{
    "end": 22, 
    "mention": "ASD ", 
    "pid": 24, 
    "senid": 5, 
    "sent": "1", 
    "start": NaN, 
    "type": "Mental_or_Behavioral_Dysfunction"
}
{
    "end": 26, 
    "mention": "VSD", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 25.0, 
    "type": "Anatomical_Abnormality"
}
{
    "end": 27, 
    "mention": "status-post", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 26.0, 
    "type": "Temporal_Concept"
}
{
    "end": 27, 
    "mention": "repair ", 
    "pid": 29, 
    "senid": 5, 
    "sent": "1", 
    "start": NaN, 
    "type": "Organism_Function"
}
{
    "end": 36, 
    "mention": "M-mode echocardiography .", 
    "pid": 5, 
    "senid": 1, 
    "sent": "This report and images describe a case of atrial flutter with 2:1 conduction pattern in a 3 year-old male with d-TGA , ASD , and VSD status-post repair , which was demonstrated by M-mode echocardiography .", 
    "start": 33.0, 
    "type": "Diagnostic_Procedure"
}
